In the case of SIRT5, the most potent and cellularly active molecules described to date are the peptide derivatives 39b‐d and 39g166, 392, 394 and 40b,c395 which, used as prodrugs, displayed favorable anticancer effects in AML and breast cancer cellular and mouse models. This evidence concerns the gene SIRT5 and breast carcinoma.